JP2021525265A5 - - Google Patents

Info

Publication number
JP2021525265A5
JP2021525265A5 JP2020565857A JP2020565857A JP2021525265A5 JP 2021525265 A5 JP2021525265 A5 JP 2021525265A5 JP 2020565857 A JP2020565857 A JP 2020565857A JP 2020565857 A JP2020565857 A JP 2020565857A JP 2021525265 A5 JP2021525265 A5 JP 2021525265A5
Authority
JP
Japan
Prior art keywords
formula
group
alkyl
methyl
composite according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020565857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/063423 external-priority patent/WO2019224340A1/en
Publication of JP2021525265A publication Critical patent/JP2021525265A/ja
Publication of JP2021525265A5 publication Critical patent/JP2021525265A5/ja
Pending legal-status Critical Current

Links

JP2020565857A 2018-05-25 2019-05-24 ピロロベンゾジアゼピン複合体 Pending JP2021525265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676407P 2018-05-25 2018-05-25
US62/676,407 2018-05-25
PCT/EP2019/063423 WO2019224340A1 (en) 2018-05-25 2019-05-24 Pyrrolobenzodiazepine conjugates

Publications (2)

Publication Number Publication Date
JP2021525265A JP2021525265A (ja) 2021-09-24
JP2021525265A5 true JP2021525265A5 (cg-RX-API-DMAC7.html) 2022-05-31

Family

ID=66677112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565857A Pending JP2021525265A (ja) 2018-05-25 2019-05-24 ピロロベンゾジアゼピン複合体

Country Status (5)

Country Link
US (1) US20210283141A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801630A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021525265A (cg-RX-API-DMAC7.html)
CN (1) CN112203696A (cg-RX-API-DMAC7.html)
WO (1) WO2019224340A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11791309B2 (en) 2018-12-12 2023-10-17 Heraeus Materials Singapore Pte. Ltd. Process for electrically connecting contact surfaces of electronic components
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質dc−81およびその製造法
ES2260570T3 (es) 1998-08-27 2006-11-01 Spirogen Limited Pirrolobenziodiazepinas dimericas.
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
AU2007351866C1 (en) * 2003-06-20 2013-07-25 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
ES2398975T3 (es) 2004-03-01 2013-03-25 Spirogen Sàrl Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2
ES2338696T3 (es) 2005-04-21 2010-05-11 Spirogen Limited Pirrolobenzodiazepinas.
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
JP6014596B2 (ja) * 2010-11-09 2016-10-25 メディミューン,エルエルシー 均一コンジュゲーションのための抗体足場
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
PT2906253T (pt) * 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
AU2013366493B2 (en) * 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
PE20181302A1 (es) * 2015-12-04 2018-08-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-claudina y sus metodos de uso
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AR111963A1 (es) * 2017-05-26 2019-09-04 Univ California Método y moléculas

Similar Documents

Publication Publication Date Title
JP2022537158A5 (cg-RX-API-DMAC7.html)
JP2019536740A5 (cg-RX-API-DMAC7.html)
JP2024545233A5 (cg-RX-API-DMAC7.html)
JP2019532056A5 (cg-RX-API-DMAC7.html)
JP6743015B2 (ja) Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類)
JP6862435B2 (ja) 抗wt1/hla特異的抗体
RU2019138337A (ru) Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии
ES2815098T3 (es) Conjugados de ligadores (ADCs) con inhibidores de KSP
RU2476441C2 (ru) Cd19-связывающие средства и их применение
JP2021527431A5 (cg-RX-API-DMAC7.html)
JP2024535637A5 (cg-RX-API-DMAC7.html)
JP2021523147A5 (cg-RX-API-DMAC7.html)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2013056885A5 (cg-RX-API-DMAC7.html)
JP2018511628A5 (cg-RX-API-DMAC7.html)
RU2019122802A (ru) Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
RU2014124984A (ru) Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
JP2015535828A5 (cg-RX-API-DMAC7.html)
JP2023547323A5 (cg-RX-API-DMAC7.html)
EA039072B1 (ru) Производные майтанзиноида, их конъюгаты и способы применения
RU2018118061A (ru) Композиция для лечения рака, экспрессирующего igf-1r
HRP20200032T1 (hr) Antitijelo lijek konjugati
JP2017528467A5 (cg-RX-API-DMAC7.html)
CN105641707B (zh) 细胞毒素分子同细胞结合受体分子的共轭体
CN119136840A (zh) 喜树碱类衍生物及配体-药物偶联物